木豆种子萌发和幼苗生长过程中的芹菜素与木犀草素含量变化

在木豆种子萌发和幼苗生长过程中,芹菜素与木犀草素含量呈波动型上升,各个器官中的木犀草素含量均高于芹菜素。种子萌发过程中,芹菜素与木犀草素最高含量分别是其在干种子的3．04和4．47倍。幼苗生长过程中,根中芹菜素和木犀草素含量高于茎和叶,芹菜素最高含量是茎和叶的1．5和1．6倍,木犀草素最高含量是茎和叶的4．4和4.2倍。二者在茎和叶中的含量及其变化趋势都基本上相似,平缓上升。     

不同品种菊花和贵州产野菊花中木犀草素的含量比较

目的测定并比较不同品种菊花和贵州产野菊花中木犀草素的含量。方法用高效液相色谱法测定木犀草素的含量。色谱柱为ODS柱（4．6mm×250mm,5μm）,流动相为甲醇-水-冰醋酸（体积比45：55：0．4）,检测波长为254nm,流速1．0mL／min。结果7个菊花样品的木犀草素含量,以贵州野菊花的木犀草素含量最高（3．876mg／g）,杭菊的木犀草素含量最低（0．302mg／g）。结论贵州产野菊花中木犀草素的含量均高于其他品种菊花,具有较高的药用价值。     

木犀草素对金黄色葡萄球菌的抑菌活性及其机制

【目的】研究木犀草素对金黄色葡萄球菌的抑制活性及其机制。【方法】利用2,3,5-氯化三苯基四氮唑(TTC)染色,细胞膜渗透性测定,SDS-PAGE蛋白谱变化,4′,6-二脒基-2-苯基吲哚(DAPI)荧光染色法等对木犀草素的抑菌活性及其机制进行研究。【结果】木犀草素能影响金黄色葡萄球菌细胞膜的通透性,木犀草素作用16h,菌体可溶性蛋白总量减少64.54%,DNA含量减少48.44%,RNA含量减少39.35%,木犀草素的浓度为1.6mg/mL时,拓扑异构酶I和II的活性可完全被抑制。【结论】木犀草素有明显的抑菌活性,其抑菌机制主要是通过抑制DNA拓扑异构酶的活性,进而影响菌体核酸及蛋白质的合成来实现的。     

不同海拔高度五脉绿绒蒿中槲皮素和木犀草素含量变化

采用HPLC法测定了青海达里加山和拉鸡山地区不同海拔五脉绿绒蒿的槲皮素和木犀草素含量.达里加山样品中槲皮素和木犀草素平均含量分别为0.1040和0.1299 mg/g,拉鸡山样品中分别为0.0719和0.2018 mg/g.结果表明,五脉绿绒蒿中槲皮素和木犀草素含量在青海达里加山地区呈现出随海拔升高而趋于增高的明显变化趋势,但在拉鸡山地区则呈现出先降后升的变化趋势,其内在变化规律尚待深入探究.     

木犀草素-锡(Ⅱ)配合物的合成、表征及抗氧化活性研究

木犀草素与金属离子有较强的配位能力,形成配合物后,活性会发生变化,因此研究了木犀草素与锡(Ⅱ)配合物的合成及其抗氧化活性。采用紫外可见分光光度法、红外光谱法和核磁共振氢谱法对配合物的结构进行表征,并通过DPPH自由基法和邻二氮菲-Fe2+法分别测定了木犀草素-锡(Ⅱ)配合物对DPPH自由基和羟基自由基(.OH)的清除作用。结果表明,木犀草素与锡(Ⅱ)发生配位的位点在5-OH～4-C=O位和3’,4’-OH位,木犀草素-锡(Ⅱ)配合物具备一定的清除DPPH自由基和.OH自由基的性能,但是由于二价锡离子与木犀草素分子中的活性位点(酚羟基)发生了配位络合,所以清除上述自由基的性能较木犀草素均有所降低。     

木犀草素改善低温下离体大鼠心脏保存效果的研究

目的:研究木犀草素是否能改善心脏停搏保存液(UW液)对离体大鼠心脏的低温保存效果。方法:将40只成年SD大鼠随机分成4组(n=10):对照组(UW组)、7.5μmol/L木犀草素小剂量组,15μmol/L木犀草素中剂量组及30μmol/L木犀草素大剂量组。利用Langendorff离体心脏灌流法,观察心脏在4℃含或不含木犀草素的UW液中保存12 h复灌60 min后心脏功能及超微结构变化,比较心脏冠脉流量(CF)、心肌含水量及冠脉流出液中磷酸肌酸激酶(CK)的释放量。结果:与对照组比较,添加木犀草素后,复灌期心脏的收缩功能(LVPSP,+dp/dtmax)与心脏舒张功能(-dp/dtmax)、冠脉流量在多个复灌时间点均优于对照组,心率在复灌60 min时也显著优于对照组;复灌过程中磷酸肌酸激酶的漏出量及低温保存后心脏超微结构的损伤也均明显低于对照组;随灌注时间延长木犀草素组心脏结构和功能的改善有剂量依赖性趋势;木犀草素对心肌含水量没有影响。结论:木犀草素能显著改善UW液对离体大鼠心脏的低温保存效果,对心脏有明显的保护作用,以30μmol/L的木犀草素大剂量组作用最显著。     

木犀草素负向调节核糖体蛋白S12表达抑制MDA-MB-231细胞增殖与侵袭CSCD

木犀草素(luteolin,Lut)对多种肿瘤细的生长具有抑制作用,但对乳腺癌细胞的生物学行为的影响尚不明确,本研究旨在探讨Lut对乳腺癌细胞增殖与侵袭的影响及其作用机制。首先体外培养乳腺癌细胞(MDA-MB-231和MCF7),免疫印迹实验检测细胞静息状态下核糖体蛋白S12(ribosomal protein S12,RPS12)表达水平。并采用MTT法、免疫印迹法分别测定不同浓度Lut处理后细胞的增殖水平,胞内RPS12及c-Myc的表达,以及PI3K/Akt、mTOR和S6K的磷酸化。同时采用c-Myc及PI3K/Akt、mTOR抑制剂处理组细胞,分别检测细胞增殖水平以及细胞内RPS12以及c-Myc表达。随后构建RPS12启动子报告基因,研究Lut对其转录的影响。最后在细胞内过表达c-Myc,或采用siRNA沉默RPS12表达,检测细胞侵袭和迁移的变化。结果显示,RPS12在乳腺癌细胞系MDA-MB-231和MCF7细胞系中均呈高水平表达。采用不同浓度Lut处理细胞后,其增殖均明显降低,PI3K/Akt、mTOR及S6K磷酸化水平与对照组相比有所减弱,c-Myc和RPS12表达也显著受到抑制,PI3K/Ak和mTOR抑制剂也具有类似结果。此外,抑制c-Myc后可显著降低乳腺癌细胞内RPS12表达以及转录活性,但细胞过表达c-Myc后RPS12水平显著增高,而沉默RPS12则可以显著抑制细胞的侵袭和迁移。以上结果表明Lut能够抑制乳腺癌细胞系MDA-MB-231的增殖与侵袭,其机制可能与抑制PI3K/Akt/mTOR信号通路进而下调c-Myc的表达,最终抑制RPS12表达有关。     

木犀草素是具有PPARγ激动剂活性的新型AMPK激活剂

目的:木犀草素是一种天然黄酮类化合物,早期报导其能激活PPARγ,本实验室发现其也能激活AMPK。因此本研究验证木犀草素在脂肪细胞中能否激活PPARγ和AMPK,并探究这两种活性对脂肪前体细胞分化及脂联素高聚化的影响。方法:使用LanthaScreen TR-FRET PPARγ竞争性结合检测试剂盒检测木犀草素与PPARγ的结合能力,并用PPRE转录激活报告基因体系验证木犀草素是否激活PPARγ转录活性,利用油红O染色法检测木犀草素对3T3-L1脂肪前体细胞分化的影响,采用RNA干扰沉默成熟脂肪细胞中AMPKα1,用Western Blot检测相关蛋白水平。结果:木犀草素能直接结合PPARγ,其IC50为1880 nmoL·L-1,并显示剂量依赖的PPARγ转录激活活性,抑制PPARγSer-273位点磷酸化。木犀草素能升高pAMPK(Thr-172)水平,抑制脂肪前体细胞分化,升高脂联素高聚化水平。结论:木犀草素通过激活AMPK和PPARγ调控脂肪前体细胞分化和脂联素高聚化,是一种具有PPARγ激动剂活性的新AMPK激活剂,有望成为治疗Ⅱ型糖尿病和肥胖等代谢紊乱疾病的潜在药物。     

木犀草素通过抑制p65 NF-κB、促进p85 PI3K调节微血管内皮细胞VCAM-1表达

通过抑制微血管内皮细胞血管细胞黏附分子(VCAM)-1的表达,木犀草素可阻遏中性粒细胞与微血管内皮细胞的黏附,起到抗炎作用。木犀草素调节VCAM-1表达与三条信号通路有关：丝裂原活化蛋白激酶(MAPK)、核因子kappa B (NF-κB)/IκB和磷脂酰肌醇3激酶(PI3K)/Akt通路。其中,MAPK和NF-κB/IκB通路参与VCAM-1正向调节,PI3K/Akt通路参与VCAM-1负向调节。本文研究了木犀草素对微血管内皮细胞该三条通路中的关键蛋白p38 MAPK、p65 NF-κB、p85 PI3K磷酸化。结果表明：木犀草素在反应的30s和1min促进p38 MAPK磷酸化,在30 s、1 min和5 min促进p85 PI3K磷酸化,而在30 s、1 min、5 min和30 min抑制p65 NF-κB磷酸化。阻抑p38 MAPK通路导致VCAM-1表达下调,而p38 MAPK抑制剂SB203580可通过抑制p38 MAPK磷酸化也下调VCAM-1,提示木犀草素对微血管内皮细胞VCAM-1的调节作用独立于p38 MAPK磷酸化。由此可知,木犀草素通过抑制p65 NF-κB磷酸化或促进p85 PI3K磷酸化调节微血管内皮细胞VCAM-1表达。本文为木犀草素抗炎作用的分子机制研究提供了新的线索。     

木犀草素对子痫前期大鼠滋养层细胞凋亡的影响及其机制

目的探讨木犀草素（LUT）对子痫前期（PE）大鼠滋养层细胞凋亡的影响及其机制。 方法取妊娠10 d SD大鼠,按随机数字表法随机分为对照组、模型组、20、40、60 mmol/L LUT （LUT-L、LUT-M、LUT-H）组,每组各12只,模型组和给药组大鼠皮下注射100 mg/（kg·d）亚硝基左旋精氨酸甲酯建立PE大鼠模型,对照组大鼠皮下注射等量生理盐水,每天1次,注射6 d。妊娠16 d的大鼠分别予以20、40、60 mmol/L LUT腹腔注射,对照组、模型组大鼠腹腔注射等量生理盐水,每天1次,注射5 d。测量各组大鼠妊娠10、16、21 d尾动脉血压及24 h尿蛋白水平;妊娠21 d,原位末端标记法（TUNEL）检测滋养层组织细胞凋亡情况,Western blot法检测滋养层组织B淋巴细胞瘤-2 （Bcl-2）、Bcl-2相关X蛋（Bax）、磷脂酰肌醇3-激酶（PI3K）、磷酸化PI3K （p-PI3K）、蛋白激酶B （Akt）、磷酸化AKT （p-Akt）、内皮型一氧化氮合酶（eNOS）和磷酸化eNOS （p-eNOS）蛋白表达量。多组间比较采用单因素方差分析,组间两两比较采用SNK-q检验。 结果妊娠10 d,各组大鼠尾动脉收缩压、舒张压、24 h尿蛋白含量差异无统计学意义;妊娠16 d,与对照组比较,模型组、LUT-L组、LUT-M组、LUT-H组大鼠尾动脉收缩压、舒张压、24 h尿蛋白含量升高（P均< 0.05）;妊娠21 d,与对照组比较,模型组、LUT-L组、LUT-M组、LUT-H组收缩压[（110.33±3.67）比（147.28±4.16）,（131.29±4.31）,（124.46±4.27）,（118.54±4.18）mmHg]、24 h蛋白尿、细胞凋亡率[（1.38±0.34）%,（43.45±3.72）%,（39.21±3.53）%,（27.86±3.41）%,（23.21±3.28）%]和Bax蛋白表达量均升高;Bcl-2、p-PI3K/PI3K （1.06±0.09比0.25±0.02,0.37±0.03,0.57±0.06,0.73±0.08）、p-Akt/Akt（0.87±0.08比0.11±0.01,0.23±0.03,0.56±0.07,0.78±0.06）和p-eNOS/eNOS蛋白表达水平（0.85±0.07比0.09±0.01,0.16±0.02,0.38±0.04,0.69±0.07）均降低（P均< 0.05）。与模型组比较,LUT-L组、LUT-M组、LUT-H组大鼠尾动脉收缩压、舒张压、滋养层组织细胞凋亡率和Bax蛋白表达量降低,Bcl-2、p-PI3K/PI3K、p-Akt/Akt和p-eNOS/eNOS蛋白表达量升高（P均< 0.05）。 结论LUT可抑制PE大鼠滋养层组织细胞凋亡,其机制可能与PI3K/Akt/eNOS信号通路激活,调控凋亡相关蛋白表达有关。     

毒蛇咬伤对患者凝血功能的影响及诊疗分析

目的观察毒蛇咬伤对患者凝血功能的影响,并探讨有效的诊疗方法。方法对2014年9月~2015年9月我院收治的200例毒蛇咬伤患者凝血功能的变化情况进行研究,主要包括变化的类型、变化种类数量、出现异常的时间和好转时间,并分析诊疗过程及诊疗效果。结果毒蛇咬伤患者的凝血功能会受到不同程度的影响,其中纤维蛋白原(Fib)减少较明显,异常持续时间一般在72h以内,少数患者超过72h;患者入院后立即实施伤口清理、注射抗蛇毒血清、连续肾脏替代(CRRT治疗)等诊疗措施。经治疗后,患者均恢复出院。结论毒蛇咬伤可引起明显的凝血功能异常,及时采取有效的治疗措施,可明显提高治疗效果,促进康复。     

红豆越桔活性成分研究及开发利用

红豆越桔是一种新兴的水果,其果实根茎叶中含有丰富的活性物质——花青素、黄酮、有机酸等。这些活性物质具有抗氧化损伤、清除氧自由基、抑制癌细胞、提高视力等多种作用。本文综述了国内外近年来对红豆越桔活性物质的研究概况,以及对红豆越桔产品的开发现状,并对进一步的研究提出了展望。     

Activation of blood coagulation factor VIIa with cleaved tissue factor extracellular domain and crystallization of the active complex

Exposure of blood to tissue factor leads to the formation of a high affinity tissue factor/factor VIIa complex which initiates blood coagulation. As a first step toward obtaining structural information of this enzyme system, a complex of active-site inhibited factor VIIa (F.VIIai) and soluble tissue factor (sTF) was prepared for crystallization. Crystals were obtained, but only after long incubation times. Analysis by SDS-PAGE and mass spectrometry indicated the presence of sTF fragments similar to those formed by proteolytic digestion with subtilisin (Konigsberg, W., Nemerson, Y., Fang, C., Lin, T.-C. Thromb. Haemost. 69:1171, 1993). To test the hypothesis that limited proteolysis of sTF facilitated the crystallization of the complex, sTF fragments were generated by subtilisin digestion and purified. Analysis by tandem mass spectrometry showed the presence of nonoverlapping N- and C-terminal sTF fragments encompassing more than 90% of the tissue factor extracellular domain. Enzymatic assays and binding studies demonstrated that an equimolar mixture of N- and C-terminal fragments bound to factor VIIa and fully restored cofactor activity. A complex of F.VIIai and sTF fragments was prepared for crystallization. Crystals were obtained using microseeding techniques. The best crystals had maximum dimensions of 0.12 × 0.12 × 0.6 mm and showed diffraction to a resolution of 3 Å. © 1995 Wiley-Liss, Inc.     

Introduction to the blood coagulation cascade and cloning of blood coagulation factors

The coagulation cascade that occurs in mammalian plasma involves a large number of plasma proteins that participate in a stepwise manner and eventually give rise to the formation of thrombin. This enzyme then converts fibrinogen to an insoluble fibrin clot. This series of reactions involves a number of glycoproteins that particupate as enzymes as well as cofactors. These proteins that circulate in the blood in a precursor or zymogen form are multifunctional proteins that share many common segments or domains. One group includes the vitamin K-dependent glycoproteins (prothrombin, factor IX, factor X, and protein C) that show considerable homology in both their amino acid sequences and their gene structures. The proteins that participate in the contact or early phase of the blood coagulation cascade include plasma prekallikrein, factor XII, and factor IX. The amino-terminal regions of both factor XI and plasma prekallikrein contain four tandem repeats of about 90 amino acids, and these tandem repeats show considerable amino acid sequence homology. Factor XII contains four different domains in the amino-terminai region of the protein, including a kringle structure, two growth factor domains, and type I and type II finger domains. The finger domains were first identified in fibronectin. The carboxyl-terminal portion of plasma prekallikrein, factor XII, and factor XI contains the serine or protease portion of the molecule. These various plasma proteins that share common domains appear to have evolved by gene shuffling that may have, in some cases, involved introns.     

An ethanol extract of Ramulus mori improves blood circulation by inhibiting platelet aggregation

Inappropriate platelet aggregation can cause blood coagulation and thrombosis. In this study, the effect of an ethanol extract of Ramulus mori (ERM) on blood circulation was investigated. The antithrombotic activity of ERM on rat carotid arterial thrombosis was evaluated in vivo, and the effect of ERM on platelet aggregation and blood coagulation time was evaluated ex vivo. To evaluate the safety of ERM, its cytotoxicity to platelets and its effect on tail bleeding time were assessed; ERM was not toxic to rat platelets and did not prolong bleeding time. Moreover, administering ERM to rats had a significant preventive effect on carotid arterial thrombosis in vivo, and significantly inhibited adenosine diphosphate- and collagen-induced platelet aggregation ex vivo, whereas it did not prolong coagulation periods, such as prothrombin time and activated partial thromboplastin time. The results suggest that ERM is effective in improving blood circulation via antiplatelet activity rather than anticoagulation activity.     

Luteolin inhibits proliferation and affects the function of stimulated rat synovial fibroblasts

Hyperproliferation of synovial fibroblasts is considered to be a pivotal event in the pathogenesis of rheumatoid arthritis (RA). Luteolin, a flavonoid, inhibits the proliferation of synovial fibroblasts in collagen-induced arthritic rats. Treatment with luteolin also decreases the secretion of matrix metalloprotease-1 and -3 and the expression of IL-6, IL-8, IL-15, and TGF-β. Luteolin treatment caused a delay of cells in the G₂/M phase. Interestingly, combination treatment with luteolin and TNF-α exhibited a synergistic inhibitory effect in all experiments. Western blotting demonstrated that treatment with luteolin alone or combined with TNF-α inhibited the MAPK/ERKs and PI3K-Akt pathways. These results indicate that luteolin inhibits the proliferation and partially blocks the pathogenic function of synovial fibroblasts in rheumatoid arthritis.     

竹叶青蛇咬伤中毒机制及临床研究新进展

竹叶青的毒素成分主要为血液毒素.被竹叶青蛇咬伤后的主要临床表现为出凝血功能障碍,其中最突出的表现是纤维蛋白原(Fib)严重消耗.根据2018年中国蛇伤救治专家共识,在治疗竹叶青蛇咬伤时,主要治疗措施有抗蛇毒血清的应用以及消肿止痛、预防破伤风、使用糖皮质激素等,并根据患者纤维蛋白原情况使用血制品如"新鲜冰冻血浆"及"冷沉...     

Circadian variations in coagulation and fibrinolytic factors among four different strains of mice

This study examined circadian variation in coagulation and fibrinolytic parameters among Jcl:ICR, C3H/HeN, BALB/cA, and C57BL/6J strains of mice. Plasma plasminogen activator inhibitor 1 (PAI-1) levels fluctuated in a circadian manner and peaked in accordance with the mRNA levels at the start of the active phase in all strains. Fibrinogen mRNA levels peaked at the start of rest periods in all strains, although plasma fibrinogen levels remained constant. Strain differences in plasma antithrombin (AT) activity and protein C (PC) levels were then identified. Plasma AT activity was circadian rhythmic only in Jcl:ICR, but not in other strains, although the mRNA levels remained constant in all strains. Levels of plasma PC and its mRNA fluctuated in a circadian manner only in Jcl:ICR mice, whereas those of plasma prothrombin, factor X, factor VII, prothrombin time (PT), and activated partial thrombin time (APTT) remained constant in all strains. These results suggest that genetic heterogeneity underlies phenotypic variations in the circadian rhythmicity of blood coagulation and fibrinolysis. The circadian onset of thrombotic events might be due in part to the rhythmic gene expression of coagulation and fibrinolytic factors. The present study provides fundamental information about mouse strains that will help to understand the circadian variation in blood coagulation and fibrinolysis.     

Structural investigation of the A domains of human blood coagulation factor V by molecular modeling.

Factor V (FV) is a large (2,196 amino acids) nonenzymatic cofactor in the coagulation cascade with a domain organization (A1-A2-B-A3-C1-C2) similar to the one of factor VIII (FVIII). FV is activated to factor Va (FVa) by thrombin, which cleaves away the B domain leaving a heterodimeric structure composed of a heavy chain (A1-A2) and a light chain (A3-C1-C2). Activated protein C (APC), together with its cofactor protein S (PS), inhibits the coagulation cascade via limited proteolysis of FVa and FVIIIa (APC cleaves FVa at residues R306, R506, and R679). The A domains of FV and FVIII share important sequence identity with the plasma copper-binding protein ceruloplasmin (CP). The X-ray structure of CP and theoretical models for FVIII have been recently reported. This information allowed us to build a theoretical model (994 residues) for the A domains of human FV/FVa (residues 1-656 and 1546-1883). Structural analysis of the FV model indicates that: (a) the three A domains are arranged in a triangular fashion as in the case of CP and the organization of these domains should remain essentially the same before and after activation; (b) a Type II copper ion is located at the A1-A3 interface; (c) residues R306 and R506 (cleavage sites for APC) are both solvent exposed; (d) residues 1667-1765 within the A3 domain, expected to interact with the membrane, are essentially buried; (e) APC does not bind to FVa residues 1865-1874. Several other features of factor V/Va, like the R506Q and A221V mutations; factor Xa (FXa) and human neutrophil elastase (HNE) cleavages; protein S, prothrombin and FXa binding, are also investigated.     

Comparison of surface plasmon resonance and quartz crystal microbalance in the study of whole blood and plasma coagulation

The coagulation of blood plasma and whole blood was studied with a surface plasmon resonance (SPR) based device and a quartz crystal microbalance instrument with energy dissipation detection (QCM-D). The SPR and QCM-D response signals were similar in shape but differing in time scales, reflecting differences in detection mechanisms. The QCM-D response time was longer than SPR, as a physical coupling of the sample to the substrate is required for molecules to be detected by the QCM-method. Change of sample properties within the evanescent field is sufficient for detection with SPR. Both the SPR signals and the QCM-D frequency and dissipation shifts showed dependency on concentrations of coagulation activator and sensitivity to heparin additions. The ratio of dissipation to frequency shifts, commonly considered to reflect viscoelastic properties of the sample, varied with the concentration of activator in blood plasma but not in whole blood. Additions of heparin to the thromboplastin activated whole blood sample, however, made the ratio variation reoccur. Implications of these observations for the understanding of the blood coagulation processes as well as the potential of the two methods in the clinic and in research are discussed.